A Guide to Diagnosis and Follow-up of Myelodysplastic Syndrome [Utilization Spotlight]

Myelodysplastic-960x540

Since 2012, we have been publishing a Utilization Spotlight in every issue of the Communiqué. Each Spotlight offers a quick view of utilization management best practices in action. This Spotlight is from March 2016.


Overview

Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that occur primarily in the older adult population and have a yearly incidence of 30 in 100,000 in persons 70 years and older. The eventual clinical outcome for patients with MDS relates to either bone marrow failure or leukemic transformations.


Situation

Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders that occur primarily in the older adult population and have a yearly incidence of 30 in 100,000 in persons 70 years and older. These disorders are typically associated with a hypercellular bone marrow and low peripheral blood counts, and with significant morbidity and mortality. The eventual clinical outcome for patients with MDS relates to either bone marrow failure or leukemic transformations.

Analysis

Conventional chromosome analysis is the gold standard for identification of the common, recurrent chromosome abnormalities in MDS. Cytogenetic studies can provide confirmatory evidence of clonality in MDS and can be used to provide clinical prognostic or diagnostic information.

Mayo Medical Laboratories Testing

Visit MayoMedicalLaboratories.com to view Mayo Medical Laboratories’ complete MDS test offerings.

Additional Resources

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.